JP2013173775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013173775A5 JP2013173775A5 JP2013094727A JP2013094727A JP2013173775A5 JP 2013173775 A5 JP2013173775 A5 JP 2013173775A5 JP 2013094727 A JP2013094727 A JP 2013094727A JP 2013094727 A JP2013094727 A JP 2013094727A JP 2013173775 A5 JP2013173775 A5 JP 2013173775A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf antibody
- medicament
- administered
- gemcitabine
- carboplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (8)
- 卵巣癌、原発腹膜癌または卵管癌と診断された患者を治療するための医薬であって、
以下のアミノ酸配列:
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW
INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP
HYYGSSHWYF DVWGQGTLVT VSS(配列番号:1)
を含む重鎖可変領域と、以下のアミノ酸配列:
DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF
TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ
GTKVEIKR(配列番号:2)
を含む軽鎖可変領域とを含む抗VEGF抗体、並びに、カルボプラチン及びゲムシタビンを含む化学療法レジメンを含み、
カルボプラチン及びゲムシタビンはサイクル1から開始して10サイクルまで投与され、抗VEGF抗体は、サイクル1から開始して、疾患が進行するまで投与され続ける、医薬。 - 患者が、白金感受性再発性卵巣癌と診断されている請求項1に記載の医薬。
- 前記抗VEGF抗体が、ハイブリドーマATCC HB 10709によって産生されるモノクローナル抗VEGF抗体A4.6.1と同じエピトープに結合する請求項1に記載の医薬。
- 抗VEGF抗体がヒト化抗体である請求項1に記載の医薬。
- 抗VEGF抗体がヒト化A4.6.1抗体又はその断片である請求項4に記載の医薬。
- 抗VEGF抗体がベバシズマブである請求項5に記載の医薬。
- 抗VEGF治療で治療されていない別の患者と比べた場合、患者の無進行生存が少なくとも約3ヶ月以上延長される請求項1に記載の医薬。
- 以下のアミノ酸配列:
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA PGKGLEWVGW
INTYTGEPTY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP
HYYGSSHWYF DVWGQGTLVT VSS(配列番号:1)
を含む重鎖可変領域と、以下のアミノ酸配列:
DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKVLIYF
TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ
GTKVEIKR(配列番号:2)
を含む軽鎖可変領域とを有する抗VEGF抗体の、
白金感受性再発性卵巣癌、原発腹膜癌または卵管癌と診断された患者を治療するための医薬であって、
抗VEGF抗体が、カルボプラチン及びゲムシタビンを含む化学療法レジメンと組み合わせて投与され、カルボプラチン及びゲムシタビンはサイクル1から開始して10サイクルまで投与され、抗VEGF抗体は、サイクル1から開始して、疾患が進行するまで投与され続ける、医薬
の製造のための使用。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30709510P | 2010-02-23 | 2010-02-23 | |
US61/307,095 | 2010-02-23 | ||
US35123110P | 2010-06-03 | 2010-06-03 | |
US61/351,231 | 2010-06-03 | ||
US36005910P | 2010-06-30 | 2010-06-30 | |
US61/360,059 | 2010-06-30 | ||
US201161439819P | 2011-02-04 | 2011-02-04 | |
US61/439,819 | 2011-02-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554084A Division JP2013520442A (ja) | 2010-02-23 | 2011-02-22 | 卵巣癌の治療のための抗血管新生治療 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015153726A Division JP2016020354A (ja) | 2010-02-23 | 2015-08-03 | 卵巣癌の治療のための抗血管新生治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013173775A JP2013173775A (ja) | 2013-09-05 |
JP2013173775A5 true JP2013173775A5 (ja) | 2014-04-10 |
JP6184733B2 JP6184733B2 (ja) | 2017-08-23 |
Family
ID=44476669
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554084A Withdrawn JP2013520442A (ja) | 2010-02-23 | 2011-02-22 | 卵巣癌の治療のための抗血管新生治療 |
JP2013094727A Active JP6184733B2 (ja) | 2010-02-23 | 2013-04-26 | 卵巣癌の治療のための抗血管新生治療 |
JP2015153726A Withdrawn JP2016020354A (ja) | 2010-02-23 | 2015-08-03 | 卵巣癌の治療のための抗血管新生治療 |
JP2017094206A Pending JP2017193551A (ja) | 2010-02-23 | 2017-05-10 | 卵巣癌の治療のための抗血管新生治療 |
JP2018142978A Withdrawn JP2018199683A (ja) | 2010-02-23 | 2018-07-30 | 卵巣癌の治療のための抗血管新生治療 |
JP2020126490A Pending JP2020196719A (ja) | 2010-02-23 | 2020-07-27 | 卵巣癌の治療のための抗血管新生治療 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554084A Withdrawn JP2013520442A (ja) | 2010-02-23 | 2011-02-22 | 卵巣癌の治療のための抗血管新生治療 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015153726A Withdrawn JP2016020354A (ja) | 2010-02-23 | 2015-08-03 | 卵巣癌の治療のための抗血管新生治療 |
JP2017094206A Pending JP2017193551A (ja) | 2010-02-23 | 2017-05-10 | 卵巣癌の治療のための抗血管新生治療 |
JP2018142978A Withdrawn JP2018199683A (ja) | 2010-02-23 | 2018-07-30 | 卵巣癌の治療のための抗血管新生治療 |
JP2020126490A Pending JP2020196719A (ja) | 2010-02-23 | 2020-07-27 | 卵巣癌の治療のための抗血管新生治療 |
Country Status (20)
Country | Link |
---|---|
US (7) | US8778340B2 (ja) |
EP (3) | EP3064509A3 (ja) |
JP (6) | JP2013520442A (ja) |
KR (4) | KR20180028561A (ja) |
CN (2) | CN103237810A (ja) |
AR (1) | AR080244A1 (ja) |
AU (5) | AU2011221229B2 (ja) |
BR (1) | BR112012020700A8 (ja) |
CA (2) | CA2930248A1 (ja) |
CL (1) | CL2012002326A1 (ja) |
CO (1) | CO6592072A2 (ja) |
IL (2) | IL221058B (ja) |
MA (1) | MA34059B1 (ja) |
MX (3) | MX369170B (ja) |
PH (1) | PH12016501728A1 (ja) |
RU (1) | RU2012140447A (ja) |
SG (2) | SG183414A1 (ja) |
TW (2) | TWI619509B (ja) |
UA (1) | UA114277C2 (ja) |
WO (1) | WO2011106300A2 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
EA029958B1 (ru) | 2011-09-23 | 2018-06-29 | Онкомед Фармасьютикалс, Инк. | Антитела, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение |
DK2825558T3 (da) * | 2012-03-13 | 2019-07-22 | Hoffmann La Roche | Kombinationsterapi til behandling af ovariecancer |
IN2014DN11157A (ja) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
CA2880767A1 (en) * | 2012-08-07 | 2014-02-13 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
UA120611C2 (uk) * | 2014-04-04 | 2020-01-10 | Тайхо Фармасьютікал Ко., Лтд. | Протипухлинний засіб, який містить таксанову сполуку і підсилювач протипухлинного ефекту |
CN107206067A (zh) * | 2014-05-07 | 2017-09-26 | 免疫医疗有限责任公司 | 使用抗‑ang2抗体的方法 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016011052A1 (en) | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
RU2017120388A (ru) * | 2014-11-14 | 2018-12-14 | Дженентек, Инк. | Прогнозирование ответа на антагонист vegf |
EP3349796A4 (en) | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
TW201713360A (en) * | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
EP3272771A1 (en) * | 2016-07-22 | 2018-01-24 | Centre National De La Recherche Scientifique | Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN115814076A (zh) * | 2021-07-01 | 2023-03-21 | 江苏先声药业有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
WO2023196153A1 (en) * | 2022-04-04 | 2023-10-12 | Merck Sharp & Dohme Llc | Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US991302A (en) * | 1910-03-28 | 1911-05-02 | Frederick G Hepburn | Waste-supporter. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
ES2435462T3 (es) | 1995-07-27 | 2013-12-19 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-vegf 항체 |
JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
CA2359067C (en) | 1999-01-15 | 2017-03-14 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ZA200509059B (en) | 2003-05-30 | 2007-01-31 | Genentech Inc | Treatment with anti-VEGF antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
ZA200701575B (en) * | 2004-09-03 | 2008-09-25 | Genentech Inc | Humanized anti-betA7 antagonists and uses therefor |
US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
CA2744158A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of breast cancer |
-
2011
- 2011-02-22 JP JP2012554084A patent/JP2013520442A/ja not_active Withdrawn
- 2011-02-22 KR KR1020187006794A patent/KR20180028561A/ko not_active Application Discontinuation
- 2011-02-22 SG SG2012061644A patent/SG183414A1/en unknown
- 2011-02-22 CN CN2011800204179A patent/CN103237810A/zh active Pending
- 2011-02-22 UA UAA201211033A patent/UA114277C2/uk unknown
- 2011-02-22 CN CN201910288567.6A patent/CN110227154A/zh active Pending
- 2011-02-22 US US13/032,532 patent/US8778340B2/en active Active
- 2011-02-22 WO PCT/US2011/025651 patent/WO2011106300A2/en active Application Filing
- 2011-02-22 KR KR1020197037761A patent/KR20190143480A/ko not_active Application Discontinuation
- 2011-02-22 KR KR1020187035833A patent/KR102104197B1/ko active IP Right Review Request
- 2011-02-22 KR KR1020127021909A patent/KR101839161B1/ko active IP Right Review Request
- 2011-02-22 CA CA2930248A patent/CA2930248A1/en not_active Withdrawn
- 2011-02-22 TW TW103134046A patent/TWI619509B/zh active
- 2011-02-22 BR BR112012020700A patent/BR112012020700A8/pt not_active Application Discontinuation
- 2011-02-22 AR ARP110100537A patent/AR080244A1/es unknown
- 2011-02-22 EP EP16159080.7A patent/EP3064509A3/en not_active Ceased
- 2011-02-22 AU AU2011221229A patent/AU2011221229B2/en active Active
- 2011-02-22 SG SG10201401123VA patent/SG10201401123VA/en unknown
- 2011-02-22 EP EP20162926.8A patent/EP3696194A1/en not_active Withdrawn
- 2011-02-22 MA MA35198A patent/MA34059B1/fr unknown
- 2011-02-22 MX MX2016010753A patent/MX369170B/es unknown
- 2011-02-22 TW TW100105846A patent/TWI457135B/zh active
- 2011-02-22 MX MX2012009554A patent/MX2012009554A/es not_active Application Discontinuation
- 2011-02-22 EP EP11706712A patent/EP2539367A2/en not_active Ceased
- 2011-02-22 RU RU2012140447/15A patent/RU2012140447A/ru not_active Application Discontinuation
- 2011-02-22 CA CA2787952A patent/CA2787952C/en active Active
-
2012
- 2012-07-22 IL IL221058A patent/IL221058B/en active IP Right Grant
- 2012-08-01 CO CO12129535A patent/CO6592072A2/es unknown
- 2012-08-16 MX MX2019000425A patent/MX2019000425A/es unknown
- 2012-08-22 CL CL2012002326A patent/CL2012002326A1/es unknown
-
2013
- 2013-04-26 JP JP2013094727A patent/JP6184733B2/ja active Active
-
2014
- 2014-01-16 US US14/157,351 patent/US20140178371A1/en not_active Abandoned
-
2015
- 2015-08-03 JP JP2015153726A patent/JP2016020354A/ja not_active Withdrawn
- 2015-08-10 AU AU2015210479A patent/AU2015210479A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,332 patent/US20160279241A1/en active Pending
- 2016-09-01 PH PH12016501728A patent/PH12016501728A1/en unknown
-
2017
- 2017-01-31 US US15/421,184 patent/US20170143826A1/en not_active Abandoned
- 2017-05-10 JP JP2017094206A patent/JP2017193551A/ja active Pending
- 2017-06-26 AU AU2017204320A patent/AU2017204320B2/en active Active
-
2018
- 2018-04-10 IL IL258612A patent/IL258612B/en unknown
- 2018-07-30 JP JP2018142978A patent/JP2018199683A/ja not_active Withdrawn
- 2018-08-09 US US16/059,964 patent/US20180344847A1/en not_active Abandoned
-
2019
- 2019-05-17 AU AU2019203466A patent/AU2019203466A1/en not_active Abandoned
- 2019-07-29 AU AU2019210484A patent/AU2019210484A1/en not_active Abandoned
-
2020
- 2020-05-13 US US15/930,798 patent/US20210052728A1/en not_active Abandoned
- 2020-07-27 JP JP2020126490A patent/JP2020196719A/ja active Pending
-
2023
- 2023-01-04 US US18/149,972 patent/US20230226179A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013173775A5 (ja) | ||
JP2017514795A5 (ja) | ||
JP2013520442A5 (ja) | ||
HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
JP2015532292A5 (ja) | ||
JP2017501157A5 (ja) | ||
HRP20191449T1 (hr) | Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica | |
JP2020500538A5 (ja) | ||
JP2011046732A5 (ja) | ||
JP2018536624A5 (ja) | ||
JP2019506403A5 (ja) | ||
JP2013510868A5 (ja) | ||
HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
JP2012509889A5 (ja) | ||
HRP20170059T1 (hr) | Uporaba protutijela anti-vegf u kombinaciji s kemoterapijom za liječenje raka dojke | |
JP2017501167A5 (ja) | ||
JP2018508512A5 (ja) | ||
JP2018507220A5 (ja) | ||
JP2017031160A5 (ja) | ||
JP2017506227A5 (ja) | ||
RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
JP2017528476A5 (ja) | ||
JP2015519052A5 (ja) | ||
JP2017510661A5 (ja) | ||
RU2018123717A (ru) | Комбинированные лечения, их применения и способы |